These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp.
    Author: Moore CB, Law D, Denning DW.
    Journal: J Antimicrob Chemother; 1993 Dec; 32(6):831-6. PubMed ID: 8144422.
    Abstract:
    The in-vitro activity of D0870, a new triazole, was compared with amphotericin B (AMP B) and itraconazole (ITZ) against 40 Aspergillus isolates, which included 25 isolates of Aspergillus fumigatus, using a broth macro-dilution method at 37 degrees C. Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) (killing of > or = 98%) were measured. For 40 isolates, geometric mean (GM) MIC values and ranges were D0870 10.55 and 2-32, ITZ 2.26 and 0.5-64, AMP B 2.42 and 1-64 mg/L. Differences in susceptibilities between species were apparent with Aspergillus flavus (n = 5) being the most susceptible to D0870 (GM 2.64, range 2-8 mg/L). MFC values were within one dilution of the MIC value for 90% of isolates (D0870 and ITZ) and 95% of isolates (AMP B). In reproducibility studies, seven, eight and four of eight isolates retested gave MIC results within one dilution for D0870, AMP B, and ITZ, respectively. Therefore, in-vitro mould testing with D0870 is feasible and reproducible with clear MIC and MFC end-points. D0870 is active against most Aspergillus spp., but at higher concentrations than either ITZ or AMP B.
    [Abstract] [Full Text] [Related] [New Search]